World Health Organization (June 2013).
The World Health Organization (WHO) released comprehensive guidance on the continuum of HIV testing, care, and treatment and the application of antiretroviral (ARV) drugs to prevent and treat HIV. This consolidated guidance is aimed at a target audience of national HIV program managers, particularly in low and middle-income countries. The guidelines include behavioral, structural, and biomedical interventions that incorporate ARV use, and highlight new technologies developed over the past three years for the HIV response. They consolidate WHO recommendations from other guidelines and provide ARV drug guidance for varied age groups and population, such as adolescents and key populations across the continuum of care, focusing on improving linkages, retention, and adherence. The document also includes the prevention benefits of HIV drugs and provides guidance for the continued scale-up of ARV drugs for treatment and prevention in resource-limited contexts. The clinical recommendations expand antiretroviral therapy eligibility to a CD4 of 500 cells/mm3. Most of the recommendations were developed based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. The WHO consolidated guidelines are a critical step towards realizing universal ARV access and improving ARV programs.